Topical Permethrin 5% Cream: Practical Exam Notes
Identification
- Drug class: Synthetic pyrethroid ectoparasiticide (scabicide).
- Preparation: Permethrin 5% cream.
- Main indication: Scabies due to Sarcoptes scabiei.
- Do not confuse it with permethrin 1% lotion/cream rinse, which is primarily used for pediculosis (lice).
Mechanism of action
Permethrin disrupts parasite neuronal sodium-channel function, producing delayed repolarization, paralysis, and death of the mite. It has very low human percutaneous absorption, reported as less than 2%.
Katzung's Basic and Clinical Pharmacology, 16th ed., p. 1673.
Indications in dermatology
- Classical scabies: First-line topical treatment.
- Scabies in infants and children aged 2 months or older.
- Crusted scabies: Used as part of combination treatment with oral ivermectin and repeated topical therapy.
- Less commonly, it can be used for lice, but the usual lice preparation is 1% permethrin, not 5%.
Method of application for scabies
- Apply at night to clean, dry skin.
- Apply a thin layer over the entire body from neck to toes, including:
- Finger webs and toe webs
- Flexural areas
- Axillae
- Umbilicus
- Groin and genitalia
- Buttocks
- Under nails
- Leave on for 8-14 hours overnight, then wash off.
- If hands are washed during the treatment interval, reapply cream to the hands.
- A second application after 7 days is commonly advised or used when clinically necessary, because eggs may survive the first treatment.
- In infants, young children, elderly people, and immunocompromised patients, include the scalp, hairline, temples, neck, and behind the ears if involved or at risk of involvement.
Current CDC guidance lists permethrin 5% cream as a first-line prescription treatment, applied from neck to toes for 8-14 hours; more than one application about a week apart may be required. See the
CDC scabies clinical-care guidance.
Contact and environmental management
- Treat all household members and close physical or sexual contacts simultaneously, even if asymptomatic.
- Wash recently used clothes, bed linen, and towels in hot water and dry on high heat.
- Items that cannot be washed should be isolated in a sealed bag for at least 72 hours.
- Pruritus may persist for 2-4 weeks after successful therapy. This alone does not prove treatment failure.
Fitzpatrick emphasizes simultaneous treatment of close contacts because household members may be asymptomatic carriers.
Fitzpatrick's Dermatology, p. 3644.
Adverse effects
Usually mild and transient:
- Burning or stinging
- Itching
- Tingling
- Erythema
- Mild irritant or eczematous dermatitis
Post-scabetic itch can be treated with emollients, a short course of topical corticosteroid where appropriate, and oral antihistamines for symptomatic relief.
Contraindications and precautions
- Avoid in infants younger than 2 months unless a specialist advises otherwise.
- Caution in patients with prior reaction to permethrin, pyrethrins, or chrysanthemum-related products, although clinically important cross-reactivity is not well established.
- Avoid application to eyes, mucosal surfaces, and broken skin where possible.
- Systemic absorption is minimal; permethrin is generally regarded as a preferred scabicide in pregnancy when treatment is indicated.
Practical viva points
- Drug: Permethrin 5% cream.
- Diagnosis treated: Scabies.
- Mechanism: Pyrethroid that disrupts mite sodium channels.
- Contact time: 8-14 hours.
- Repeat: Usually after 7 days if needed.
- Important instruction: Treat all close contacts at the same time.
- Common error: Using 1% lice formulation instead of 5% scabies cream, or incomplete body application.
- Common adverse effects: Transient burning, stinging, and pruritus.
- Not for: Infants below 2 months without specialist direction.
Current status and recent advances: Brief
Present position
Permethrin 5% remains a first-line and widely recommended topical scabicide for ordinary scabies. It is effective, easy to use, has low systemic absorption, and is suitable for many children older than 2 months and for pregnancy when indicated.
Emerging concern: treatment failure and resistance
Clinical reports of reduced response to permethrin have increased. A 2024 review described permethrin-resistant scabies as an emerging concern, but it also stressed that the magnitude and geographic distribution of true resistance are not fully defined.
Simonart et al., 2024, PMID 39336998
Do not call every failure “resistance.” Many apparent failures are pseudo-resistance, caused by:
- Incomplete application, especially hands, finger webs, genitalia, nails, feet, or scalp when relevant
- Insufficient contact time
- Failure to repeat treatment when indicated
- Untreated household or sexual contacts
- Reinfestation
- Misdiagnosis
- Persistent post-scabetic dermatitis or itch despite eradication of mites
A 2024 systematic review/meta-analysis documented treatment failure as a clinically important issue in scabies management.
Mbuagbaw et al., 2024, PMID 37625798
What is changing in practice?
- Greater emphasis on correct, supervised whole-body application and simultaneous contact treatment.
- More frequent consideration of alternatives in persistent cases, such as oral ivermectin, benzyl benzoate, precipitated sulfur, or other locally available scabicides.
- Crusted scabies should be treated aggressively with combined oral ivermectin plus repeated topical permethrin, often with keratolytics to remove crusts.
- A 2024 randomized trial directly compared 5% permethrin with 25% benzyl benzoate, reflecting interest in alternatives where reduced permethrin sensitivity is suspected. Meyersburg et al., 2024, PMID 38112640
One-line current-status answer for an exam:
“Permethrin 5% remains first-line topical therapy for classical scabies, but rising reports of clinical failure and possible resistance mean that correct application, simultaneous treatment of contacts, and use of alternatives or combination therapy in refractory and crusted cases are increasingly important.”